

Press Release

Abliva AB (publ), 556595-6538
16 June 2020 13:00:00 CEST - Lund,
Sweden



Abliva invites you to a virtual Capital Markets Day on June 23

Abliva AB (Nasdaq Stockholm: ABLI), invites you to a virtual Capital Markets Day on 23 June at 3.00 p.m. - 4.30 p.m. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most important pharmaceutical projects and the market potential.

CEO Erik Kinnman will describe Abliva's operations, the background to the company's strategic direction and the name change (formerly NeuroVive).

Abliva's Chief Medical Officer, Magnus Hansson, and Matilda Hugerth, Director Clinical and Regulatory Affairs, will address the major medical needs in primary mitochondrial diseases, the benefits of the company's development projects being in the orphan drug field, and describe the plans and clinical developments for Abliva's key projects KL1333 and NV354..

Furthermore, Abliva's incoming board member Dr. Roger Franklin, who represents Hadean Ventures, new shareholder in Abliva, is interviewed. Hadean Ventures is a fund manager specializing in life science investments.

The program, moderated by Charlotte Stjerngren, ends with a question and answer session and studio discussion in which external analysts also participate as questioners. During the program it will be possible to ask questions to the company on ir@abliva.com. The meeting will mostly be held in Swedish.

Abliva AB is the new name that replaces the former NeuroVive Pharmaceutical AB. The name change is part of the company's focus on primary mitochondrial diseases, all of which have high unmet medical needs and are orphan indications. Abliva's main projects, KL1333 and NV354, are both focused on primary mitochondrial diseases. The company's drug candidate NeuroSTAT, is planned to be placed in a separate wholly-owned company after undiluted financing is secured in order to give the project the best opportunities for resource allocation and further development to the market.

The Capital Markets Day will be followed via Abliva's website at: <http://abliva.com/sv/investor/capital-markets-day-2020/>. The recording will also be posted afterwards. Questions can be asked to ir@abliva.com.

Welcome on June 23rd!

Press Release

Abliva AB (publ), 556595-6538
16 June 2020 13:00:00 CEST - Lund,
Sweden



For more information, please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

For news subscription, please visit: <http://abliva.com/press-releases/subscription-page/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Abliva invites you to a virtual Capital Markets Day on June 23](#)